Schonfeld Strategic Advisors LLC decreased its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 40.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 103,000 shares of the company's stock after selling 69,327 shares during the period. Schonfeld Strategic Advisors LLC owned about 0.07% of Xeris Biopharma worth $349,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Northern Trust Corp raised its position in Xeris Biopharma by 3.3% in the fourth quarter. Northern Trust Corp now owns 1,196,381 shares of the company's stock worth $4,056,000 after acquiring an additional 38,155 shares during the period. Aquatic Capital Management LLC bought a new position in Xeris Biopharma in the fourth quarter worth approximately $50,000. Susquehanna Fundamental Investments LLC bought a new position in Xeris Biopharma in the fourth quarter worth approximately $67,000. Virtus ETF Advisers LLC bought a new position in Xeris Biopharma in the fourth quarter worth approximately $71,000. Finally, Price T Rowe Associates Inc. MD raised its position in Xeris Biopharma by 5.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 170,482 shares of the company's stock worth $578,000 after acquiring an additional 9,506 shares during the period. Institutional investors own 42.75% of the company's stock.
Insiders Place Their Bets
In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This trade represents a 2.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 6.47% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on XERS. Oppenheimer increased their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners increased their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research note on Friday, March 7th. Piper Sandler reissued a "neutral" rating and issued a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Xeris Biopharma has an average rating of "Moderate Buy" and a consensus price target of $6.25.
Check Out Our Latest Stock Report on Xeris Biopharma
Xeris Biopharma Trading Down 1.0%
XERS traded down $0.05 during trading on Tuesday, hitting $4.90. 1,597,830 shares of the company traded hands, compared to its average volume of 1,937,641. The company has a market cap of $766.29 million, a PE ratio of -10.89 and a beta of 1.10. The stock's 50-day simple moving average is $4.70 and its two-hundred day simple moving average is $3.88. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.84 and a 1 year high of $6.07.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. Equities analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.
About Xeris Biopharma
(
Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Read More
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
